Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award
Philadelphia, PA – Chimeron Bio, a next generation RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary Multiplex delivery platform, announced today that the company has been recognized by MilliporeSigma as a finalist in the company's North American Advance Biotech Grant. As part of the award, Chimeron will receive in-kind products…
read more